These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1718 related items for PubMed ID: 17823083

  • 21. Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial.
    Lufkin EG, Whitaker MD, Nickelsen T, Argueta R, Caplan RH, Knickerbocker RK, Riggs BL.
    J Bone Miner Res; 1998 Nov; 13(11):1747-54. PubMed ID: 9797484
    [Abstract] [Full Text] [Related]

  • 22. Circaannual rhythms and interactions of vitamin D metabolites, parathyroid hormone, and biochemical markers of skeletal homeostasis: a prospective study.
    Woitge HW, Knothe A, Witte K, Schmidt-Gayk H, Ziegler R, Lemmer B, Seibel MJ.
    J Bone Miner Res; 2000 Dec; 15(12):2443-50. PubMed ID: 11127208
    [Abstract] [Full Text] [Related]

  • 23. Effects of growth hormone administration on bone mineral metabolism, PTH sensitivity and PTH secretory rhythm in postmenopausal women with established osteoporosis.
    Joseph F, Ahmad AM, Ul-Haq M, Durham BH, Whittingham P, Fraser WD, Vora JP.
    J Bone Miner Res; 2008 May; 23(5):721-9. PubMed ID: 18052753
    [Abstract] [Full Text] [Related]

  • 24. [Relationship between changes in biochemical markers of bone turnover and prediction value of fracture risk].
    Cyaki O.
    Clin Calcium; 2004 Oct; 14(10):39-46. PubMed ID: 15577130
    [Abstract] [Full Text] [Related]

  • 25. A comparison of raloxifene and calcium plus vitamin D on vaginal atrophy after discontinuation of long-standing postmenopausal hormone therapy in osteoporotic women. A randomized, masked-evaluator, one-year, prospective study.
    Checa MA, Garrido A, Prat M, Conangla M, Rueda C, Carreras R.
    Maturitas; 2005 Sep 16; 52(1):70-7. PubMed ID: 16143228
    [Abstract] [Full Text] [Related]

  • 26. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk.
    Reginster JY, Sarkar S, Zegels B, Henrotin Y, Bruyere O, Agnusdei D, Collette J.
    Bone; 2004 Feb 16; 34(2):344-51. PubMed ID: 14962813
    [Abstract] [Full Text] [Related]

  • 27. Relationship between circulating tumor necrosis factor system and bone mass before and after estrogen plus progestogen therapy.
    Kim JG, Ku SY, Kim H, Chun SW, Suh CS, Choi YM.
    Menopause; 2009 Feb 16; 16(3):534-8. PubMed ID: 19225428
    [Abstract] [Full Text] [Related]

  • 28. Raloxifene therapy interacts with serum osteoprotegerin in postmenopausal women.
    Messalli EM, Mainini G, Scaffa C, Cafiero A, Salzillo PL, Ragucci A, Cobellis L.
    Maturitas; 2007 Jan 20; 56(1):38-44. PubMed ID: 16787719
    [Abstract] [Full Text] [Related]

  • 29. [Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis].
    Ohta H.
    Clin Calcium; 2008 Oct 20; 18(10):1442-50. PubMed ID: 18830041
    [Abstract] [Full Text] [Related]

  • 30. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in postmenopausal women: a randomized clinical trial in Beijing.
    Zheng S, Wu Y, Zhang Z, Yang X, Hui Y, Zhang Y, Chen S, Deng W, Liu H, Ekangaki A, Stocks J, Harper K, Liu J.
    Chin Med J (Engl); 2003 Aug 20; 116(8):1127-33. PubMed ID: 12935394
    [Abstract] [Full Text] [Related]

  • 31. Effect of raloxifene hydrochloride on bone mineral density and bone turnover in Kuwaiti postmenopausal women with osteoporosis.
    Abdelazim IA, Abdelrazak KM, Al-Kadi M, Yehia AH, Nusair BM, Faza MA.
    Arch Osteoporos; 2014 Aug 20; 9():189. PubMed ID: 25037077
    [Abstract] [Full Text] [Related]

  • 32. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK, Chadha M, Modi KD, Kumar KM, Mehrotra R, Sriram U.
    J Assoc Physicians India; 2008 Jun 20; 56():418-24. PubMed ID: 18822620
    [Abstract] [Full Text] [Related]

  • 33. [Effects of the combined raloxifene-sodium fluoride therapy on bone mass and bone turnover in women with postmenopausal osteoporosis].
    Celi M, Letizia C, Ragno A, Minisola S, D'Erasmo E, Mazzuoli GF.
    Minerva Med; 2002 Dec 20; 93(6):471-8. PubMed ID: 12515970
    [Abstract] [Full Text] [Related]

  • 34. [The influence of hormonal replacement therapy on bone density in postmenopausal women depending on polymorphism of vitamin D receptor (VDR) and estrogen receptor (ER) genes].
    Brodowska A.
    Ann Acad Med Stetin; 2003 Dec 20; 49():111-30. PubMed ID: 15552843
    [Abstract] [Full Text] [Related]

  • 35. Serum prolidase activity in postmenopausal osteoporosis.
    Namiduru ES, Binnur Erbagci A, Celik A, Yilmaz M, Tarakçioglu M.
    Minerva Med; 2007 Dec 20; 98(6):647-51. PubMed ID: 18299678
    [Abstract] [Full Text] [Related]

  • 36. Effect of zoledronic acid compared with raloxifene on bone turnover markers in postmenopausal women with low bone density.
    Bachmann G, Kriegman A, Gonçalves J, Kianifard F, Warren M, Simon JA.
    Menopause; 2011 Aug 20; 18(8):851-6. PubMed ID: 21796066
    [Abstract] [Full Text] [Related]

  • 37. [Biochemical markers of bone turnover. New aspect. Effects of androgen and estrogen on biochemical markers of bone turnover].
    Ohnaka K, Takayanagi R.
    Clin Calcium; 2009 Aug 20; 19(8):1118-24. PubMed ID: 19638695
    [Abstract] [Full Text] [Related]

  • 38. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
    Confavreux CB, Fontana A, Guastalla JP, Munoz F, Brun J, Delmas PD.
    Bone; 2007 Sep 20; 41(3):346-52. PubMed ID: 17618847
    [Abstract] [Full Text] [Related]

  • 39. [Effects of raloxifene on bone biomarkers in postmenopausal women on maintenance haemodialysis].
    Matsuo K, Fujinaga M, Tsuchiya K, Nakamoto M, Yasunaga C.
    Clin Calcium; 2005 Sep 20; 15 Suppl 1():92-6; discussion 96-7. PubMed ID: 16272639
    [Abstract] [Full Text] [Related]

  • 40. Effects of administration of hormone therapy or raloxifene on the immune system and on biochemical markers of bone remodeling.
    Pineda B, Hermenegildo C, Tarín JJ, Cano A, García-Pérez MÁ.
    Menopause; 2012 Mar 20; 19(3):319-27. PubMed ID: 22067277
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 86.